We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Robot Assists Endoscopic Transmyocardial Revascularization

By HospiMedica staff writers
Posted on 04 Dec 2007
A robotic surgical system that utilizes an endoscopic approach to achieve transmyocardial revascularization (TMR) can reduce patient hospitalization and recovery time.

The Port Enabled Angina Relief using Laser (PEARL) system is intended for endoscopic TMR in patients with advanced coronary artery disease. More...
The system consists of a flexible fiberoptic hand-piece that delivers precise bursts of holmium:YAG laser energy directly to an area of ischemic myocardium. The handpiece is equipped with an extended length shaft, which can be introduced via a laparoscopic approach under general anesthesia. The distal end of the shaft is flexible, and is designed to enable the grasping and manipulation of the tip by surgical robotic tools, enabling precise target area placement. Once in the proper position, the handpiece control is used to create a series of laser channels approximately one-millimeter in diameter. During a typical procedure, approximately 20 - 35 channels are made in the heart muscle; 6-10 pulses are needed to transverse the myocardium and create the channels.

The outside punctures seal over with little blood loss while the new channels allow fresh blood to perfuse the heart wall immediately, and may provide oxygen in the process. How TMR actually reduces angina is not fully understood. Researchers speculate that the laser may stimulate angiogenesis, or that it may destroy nerve fibers to the heart, making patients unable to feel their chest pain. Angina usually subsides with improved oxygen supply to the damaged areas of heart muscle. The PEARL is a product of Cardiogenesis (Irvine, CA, USA), and has been approved by the [U.S.] Food and Drug Administration (FDA).

TMR is indicated in patients whose chronic angina symptoms are not relieved by medication and who are not candidates for percutaneous coronary intervention or coronary artery bypass graft (CABG) surgery.


Related Links:
Cardiogenesis

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.